Cost-Benefit Analysis of Preventing Nosocomial Bloodstream Infections among Hemodialysis Patients in Canada in 2004 (English)
- New search for: Hong, Z.
- New search for: Wu, J.
- New search for: Tisdell, C.
- New search for: O'Leary, C.
- New search for: Gomes, J.
- New search for: Wen, S. W.
- New search for: Njoo, H.
- New search for: Hong, Z.
- New search for: Wu, J.
- New search for: Tisdell, C.
- New search for: O'Leary, C.
- New search for: Gomes, J.
- New search for: Wen, S. W.
- New search for: Njoo, H.
In:
VALUE IN HEALTH
;
13
, 1
;
42-45
;
2010
-
ISSN:
- Article (Journal) / Print
-
Title:Cost-Benefit Analysis of Preventing Nosocomial Bloodstream Infections among Hemodialysis Patients in Canada in 2004
-
Contributors:Hong, Z. ( author ) / Wu, J. ( author ) / Tisdell, C. ( author ) / O'Leary, C. ( author ) / Gomes, J. ( author ) / Wen, S. W. ( author ) / Njoo, H. ( author )
-
Published in:VALUE IN HEALTH ; 13, 1 ; 42-45
-
Publisher:
- New search for: Blackwell Publishing Ltd
-
Publication date:2010-01-01
-
Size:4 pages
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 610
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 610 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 13, Issue 1
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 1
-
Beyond AWP . . . Way BeyondWillke, R. J. et al. | 2010
- 2
-
What's in a Perspective?Glick, H. A. et al. | 2010
- 3
-
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report-Part IHay, J. W. / Smeeding, J. / Carroll, N. V. / Drummond, M. / Garrison, L. P. / Mansley, E. C. / Mullins, C. D. / Mycka, J. M. / Seal, B. / Shi, L. et al. | 2010
- 8
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report-Part IIGarrison, L. P. / Mansley, E. C. / Abbott, T. A. / Bresnahan, B. W. / Hay, J. W. / Smeeding, J. et al. | 2010
- 14
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective: The ISPOR Drug Cost Task Force Report-Part IIIMansley, E. C. / Carroll, N. V. / Chen, K. S. / Shah, N. D. / Piech, C. T. / Hay, J. W. / Smeeding, J. et al. | 2010
- 18
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report-Part IVMullins, C. D. / Seal, B. / Seoane-Vazquez, E. / Sankaranarayanan, J. / Asche, C. V. / Jayadevappa, R. / Lee, W. C. / Romanus, D. K. / Wang, J. / Hay, J. W. et al. | 2010
- 25
-
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An Industry Perspective: The ISPOR Drug Cost Task Force Report-Part VMycka, J. M. / Dellamano, R. / Kolassa, E. M. / Wonder, M. / Ghosh, S. / Hay, J. W. / Smeeding, J. et al. | 2010
- 28
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report-Part VIShi, L. / Hodges, M. / Drummond, M. / Ahn, J. / Li, S. C. / Hu, S. / Augustovski, F. / Hay, J. W. / Smeeding, J. et al. | 2010
- 34
-
The Multinational Nature of Cost-Effectiveness Analyses Alongside Multinational Clinical TrialsRivero-Arias, O. / Gray, A. et al. | 2010
- 42
-
Cost-Benefit Analysis of Preventing Nosocomial Bloodstream Infections among Hemodialysis Patients in Canada in 2004Hong, Z. / Wu, J. / Tisdell, C. / O'Leary, C. / Gomes, J. / Wen, S. W. / Njoo, H. et al. | 2010
- 46
-
The Impact of Fewer Hip Fractures with Risedronate Versus Alendronate in the First Year of Treatment: Modeled German Cost-Effectiveness AnalysisThompson, M. / Pasquale, M. / Grima, D. / Moehrke, W. / Kruse, H. P. et al. | 2010
- 55
-
Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell CarcinomaHoyle, M. / Green, C. / Thompson-Coon, J. / Liu, Z. / Welch, K. / Moxham, T. / Stein, K. et al. | 2010
- 61
-
Cost-Effectiveness of Temsirolimus for First Line Treatment of Advanced Renal Cell CarcinomaHoyle, M. / Green, C. / Thompson-Coon, J. / Liu, Z. / Welch, K. / Moxham, T. / Stein, K. et al. | 2010
- 69
-
Budget Impact Analysis of Thrombolysis for Stroke in Spain: A Discrete Event Simulation ModelMar, J. / Arrospide, A. / Comas, M. et al. | 2010
- 77
-
Prevalence of Respiratory Syncytial Virus (RSV) Risk Factors and Cost Implications of Immunoprophylaxis to Infants 32 to 35 Weeks Gestation for Health Plans in the United StatesKrilov, L. R. / Palazzi, D. L. / Fernandes, A. W. / Klein, R. W. / Mahadevia, P. J. et al. | 2010
- 87
-
Relationship between Adherence Level to Statins, Clinical Issues and Health-Care Costs in Real-Life Clinical SettingDragomir, A. / Cote, R. / White, M. / Lalonde, L. / Blais, L. / Berard, A. / Perreault, S. et al. | 2010
- 95
-
Relationship between Health-Related Quality of Life, Pain, and Functional Disability in Neuropathic Pain Patients with Failed Back Surgery SyndromeManca, A. / Eldabe, S. / Buchser, E. / Kumar, K. / Taylor, R. S. et al. | 2010
- 103
-
A Multinational Study of Health State Preference Values Associated with Chronic Myelogenous LeukemiaSzabo, S. M. / Levy, A. R. / Davis, C. / Holyoake, T. L. / Cortes, J. et al. | 2010
- 112
-
Patient Characteristics Impacting Health State Index Scores, Measured by the EQ-5D of Females with Stress Urinary Incontinence SymptomsTincello, D. / Sculpher, M. / Tunn, R. / Quail, D. / van der Vaart, H. / Falconer, C. / Manning, M. / Timlin, L. et al. | 2010
- 119
-
Psychometric Development of the Individualized Retinopathy-Dependent Quality of Life Questionnaire (RetDQoL)Brose, L. S. / Bradley, C. et al. | 2010
- 128
-
A Methodology for Successfully Producing Global Translations of Patient Reported Outcome Measures for Use in Multiple CountriesTwo, R. / Verjee-Lorenz, A. / Clayson, D. / Dalal, M. / Grotzinger, K. / Younossi, Z. M. et al. | 2010
- 132
-
Instrumental Variables in Influenza Vaccination Studies: Mission Impossible?!Groenwold, R. H. / Hak, E. / Klungel, O. H. / Hoes, A. W. et al. | 2010
- 138
-
Relationships among Self-Management, Patient Perceptions of Care, and Health Economic Outcomes for Decision-Making and Clinical Practice in Type 2 DiabetesCobden, D. S. / Niessen, L. W. / Barr, C. E. / Rutten, F. F. / Redekop, W. K. et al. | 2010
- 148
-
The Impact of Pharmaceutical Cost Containment Policies on the Range of Medicines Available and Subsidized in Finland and New ZealandAaltonen, K. / Ragupathy, R. / Tordoff, J. / Reith, D. / Norris, P. et al. | 2010
- 157
-
Calibration of Disease Simulation Model Using an Engineering ApproachVanni, T. / Legood, R. / White, R. G. et al. | 2010
- 158
-
Erratum| 2010
- viii
-
ISPOR CODE OF ETHICS:MARCH 2008| 2010